Tamoxifen treatment for precocious puberty in McCune-Albright syndrome

A multicenter trial

Erica Eugster, Stephen D. Rubin, Edward O. Reiter, Paul Plourde, Hann Chang Jou, Ora H. Pescovitz

Research output: Contribution to journalArticle

95 Citations (Scopus)

Abstract

Objective: We undertook a 1-year multicenter trial of tamoxifen treatment for precocious puberty in girls with McCune-Albright syndrome (MAS). Study design: Girls ≤ 10 years with classic or atypical MAS were recruited. Pretreatment history was collected for 6 months. Patients received 20 mg tamoxifen daffy. Diaries were used to record bleeding. Evaluations included physical examination, bone age, pelvic ultrasound, hormone levels, and safety assessments. Results: A total of 2S girls (2.9-10.9 years of age) were enrolled from 20 centers, of whom 25 completed 12 months of tamoxifen treatment. Compared with before the study, vaginal bleeding episodes decreased (3.42 ± 3.36/year vs 1.17 ± 1.41/year), growth velocity slowed (SDS 1.22 ± 2.6,5 vs-0.59 ± 3.06, P = .005), and rate of bone maturation decreased (1.21 ± 0.78 vs 0.72 ± 0.36, P = .02). Ovarian volumes were enlarged and asymmetric throughout the study, and uterine volumes were increased. No adverse events occurred. Conclusions: Tamoxifen treatment of precocious puberty in MAS results in a reduction of vaginal bleeding and significant improvements in growth velocity and rate of skeletal maturation.

Original languageEnglish
Pages (from-to)60-66
Number of pages7
JournalJournal of Pediatrics
Volume143
Issue number1
DOIs
StatePublished - Jul 1 2003

Fingerprint

Polyostotic Fibrous Dysplasia
Precocious Puberty
Tamoxifen
Multicenter Studies
Uterine Hemorrhage
Pelvic Bones
Therapeutics
Growth
Physical Examination
History
Hormones
Hemorrhage
Safety
Bone and Bones

ASJC Scopus subject areas

  • Pediatrics, Perinatology, and Child Health

Cite this

Tamoxifen treatment for precocious puberty in McCune-Albright syndrome : A multicenter trial. / Eugster, Erica; Rubin, Stephen D.; Reiter, Edward O.; Plourde, Paul; Jou, Hann Chang; Pescovitz, Ora H.

In: Journal of Pediatrics, Vol. 143, No. 1, 01.07.2003, p. 60-66.

Research output: Contribution to journalArticle

Eugster, Erica ; Rubin, Stephen D. ; Reiter, Edward O. ; Plourde, Paul ; Jou, Hann Chang ; Pescovitz, Ora H. / Tamoxifen treatment for precocious puberty in McCune-Albright syndrome : A multicenter trial. In: Journal of Pediatrics. 2003 ; Vol. 143, No. 1. pp. 60-66.
@article{100cd1187a234aa1a971d25898f988ef,
title = "Tamoxifen treatment for precocious puberty in McCune-Albright syndrome: A multicenter trial",
abstract = "Objective: We undertook a 1-year multicenter trial of tamoxifen treatment for precocious puberty in girls with McCune-Albright syndrome (MAS). Study design: Girls ≤ 10 years with classic or atypical MAS were recruited. Pretreatment history was collected for 6 months. Patients received 20 mg tamoxifen daffy. Diaries were used to record bleeding. Evaluations included physical examination, bone age, pelvic ultrasound, hormone levels, and safety assessments. Results: A total of 2S girls (2.9-10.9 years of age) were enrolled from 20 centers, of whom 25 completed 12 months of tamoxifen treatment. Compared with before the study, vaginal bleeding episodes decreased (3.42 ± 3.36/year vs 1.17 ± 1.41/year), growth velocity slowed (SDS 1.22 ± 2.6,5 vs-0.59 ± 3.06, P = .005), and rate of bone maturation decreased (1.21 ± 0.78 vs 0.72 ± 0.36, P = .02). Ovarian volumes were enlarged and asymmetric throughout the study, and uterine volumes were increased. No adverse events occurred. Conclusions: Tamoxifen treatment of precocious puberty in MAS results in a reduction of vaginal bleeding and significant improvements in growth velocity and rate of skeletal maturation.",
author = "Erica Eugster and Rubin, {Stephen D.} and Reiter, {Edward O.} and Paul Plourde and Jou, {Hann Chang} and Pescovitz, {Ora H.}",
year = "2003",
month = "7",
day = "1",
doi = "10.1016/S0022-3476(03)00128-8",
language = "English",
volume = "143",
pages = "60--66",
journal = "Journal of Pediatrics",
issn = "0022-3476",
publisher = "Mosby Inc.",
number = "1",

}

TY - JOUR

T1 - Tamoxifen treatment for precocious puberty in McCune-Albright syndrome

T2 - A multicenter trial

AU - Eugster, Erica

AU - Rubin, Stephen D.

AU - Reiter, Edward O.

AU - Plourde, Paul

AU - Jou, Hann Chang

AU - Pescovitz, Ora H.

PY - 2003/7/1

Y1 - 2003/7/1

N2 - Objective: We undertook a 1-year multicenter trial of tamoxifen treatment for precocious puberty in girls with McCune-Albright syndrome (MAS). Study design: Girls ≤ 10 years with classic or atypical MAS were recruited. Pretreatment history was collected for 6 months. Patients received 20 mg tamoxifen daffy. Diaries were used to record bleeding. Evaluations included physical examination, bone age, pelvic ultrasound, hormone levels, and safety assessments. Results: A total of 2S girls (2.9-10.9 years of age) were enrolled from 20 centers, of whom 25 completed 12 months of tamoxifen treatment. Compared with before the study, vaginal bleeding episodes decreased (3.42 ± 3.36/year vs 1.17 ± 1.41/year), growth velocity slowed (SDS 1.22 ± 2.6,5 vs-0.59 ± 3.06, P = .005), and rate of bone maturation decreased (1.21 ± 0.78 vs 0.72 ± 0.36, P = .02). Ovarian volumes were enlarged and asymmetric throughout the study, and uterine volumes were increased. No adverse events occurred. Conclusions: Tamoxifen treatment of precocious puberty in MAS results in a reduction of vaginal bleeding and significant improvements in growth velocity and rate of skeletal maturation.

AB - Objective: We undertook a 1-year multicenter trial of tamoxifen treatment for precocious puberty in girls with McCune-Albright syndrome (MAS). Study design: Girls ≤ 10 years with classic or atypical MAS were recruited. Pretreatment history was collected for 6 months. Patients received 20 mg tamoxifen daffy. Diaries were used to record bleeding. Evaluations included physical examination, bone age, pelvic ultrasound, hormone levels, and safety assessments. Results: A total of 2S girls (2.9-10.9 years of age) were enrolled from 20 centers, of whom 25 completed 12 months of tamoxifen treatment. Compared with before the study, vaginal bleeding episodes decreased (3.42 ± 3.36/year vs 1.17 ± 1.41/year), growth velocity slowed (SDS 1.22 ± 2.6,5 vs-0.59 ± 3.06, P = .005), and rate of bone maturation decreased (1.21 ± 0.78 vs 0.72 ± 0.36, P = .02). Ovarian volumes were enlarged and asymmetric throughout the study, and uterine volumes were increased. No adverse events occurred. Conclusions: Tamoxifen treatment of precocious puberty in MAS results in a reduction of vaginal bleeding and significant improvements in growth velocity and rate of skeletal maturation.

UR - http://www.scopus.com/inward/record.url?scp=0041353103&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0041353103&partnerID=8YFLogxK

U2 - 10.1016/S0022-3476(03)00128-8

DO - 10.1016/S0022-3476(03)00128-8

M3 - Article

VL - 143

SP - 60

EP - 66

JO - Journal of Pediatrics

JF - Journal of Pediatrics

SN - 0022-3476

IS - 1

ER -